Double Blind Bio

Name: Double Blind Bio
Brand: Double Blind Bio

AI Native

AI agents automating site and sponsor workflows so trials move faster without adding headcount.

Est 2025

LinkedIn 669|Website|FTEs 9|HQ San Francisco, California, US

Where Double Blind Bio appears differentiated (based on public positioning): - Emphasis on site-side trial discovery and proactive outreach rather than only sponsor-side feasibility workflows. - Reuse of feasibility responses to avoid repeated manual entry. - Presence in a partner directory (CRIO) suggesting at least one integration path into a commonly used site platform. Where alternatives may be stronger: - Enterprise clinical platforms (Veeva, Oracle, Medidata) often provide a consolidated validated environment with mature compliance posture and broad, cross-functional adoption. - Feasibility specialists (Yendou, Trial Interactive, Research Grid) may offer deeper sponsor/CRO workflows, scoring models, and operational reporting. Market adoption signals (limited): - Inclusion in the CRIO partner directory indicates channel visibility to site customers. - Small company size and early-stage funding suggest a product in a scaling phase, which implies potential responsiveness and higher execution risk.

01Competitive Landscape

Narrative competitive analysis

Where Double Blind Bio appears differentiated (based on public positioning):

Emphasis on site-side trial discovery and proactive outreach rather than only sponsor-side feasibility workflows.
Reuse of feasibility responses to avoid repeated manual entry.
Presence in a partner directory (CRIO) suggesting at least one integration path into a commonly used site platform.

Where alternatives may be stronger:

Enterprise clinical platforms (Veeva, Oracle, Medidata) often provide a consolidated validated environment with mature compliance posture and broad, cross-functional adoption.
Feasibility specialists (Yendou, Trial Interactive, Research Grid) may offer deeper sponsor/CRO workflows, scoring models, and operational reporting.

Market adoption signals (limited):

Inclusion in the CRIO partner directory indicates channel visibility to site customers.
Small company size and early-stage funding suggest a product in a scaling phase, which implies potential responsiveness and higher execution risk.

	Double Blind Bio	Yendou (Feasibility)	Trial Interactive eFeasibility
Starting Price	Not public (demo/quote)	Not public (demo/quote)	Not public (demo/quote)
Primary users	Research sites seeking trial discovery and feasibility automation	Sponsors/CROs and site ops teams focused on feasibility capture	Sponsors/CROs needing feasibility surveys and site scoring in an eClinical ecosystem
Key Strength	Focus on site-side trial discovery and reuse of feasibility data; CTMS/eReg connectivity described	Feasibility workflow focus; publishes vendor-claimed performance metrics	Established eClinical vendor with feasibility and scoring features
Key Weakness	Limited publicly accessible independent reviews and case studies; security posture not publicly detailed	Vendor metrics should be validated for generalizability	May be enterprise-oriented and less focused on site-side growth workflows

Double Blind Bio

01Competitive Landscape

Narrative competitive analysis

02Market Map

01Competitive Landscape

Narrative competitive analysis

02Market Map